ClinicalTrials.gg
CompletedNCT03053440ASPENUpdated Oct 26, 2024Results posted

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

A Phase 3 interventional study of BGB-3111 and Ibrutinib in Waldenström's Macroglobulinemia, sponsored by BeiGene. Completed at 58 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia — 2 open to participants now, 7 under way, 2 of them phase 3. ibrutinib · Waldenstrom Macroglobulinemia.

Enrollment
2nd of 25
201 · median 48
Started
2017
with 1 other
Phase 3
4 of 25
none open now
Registered
13th of 25
by date
Lead sponsor
1 of 25
BeiGene

Among the 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia, this one is the 2nd largest by enrollment, is one of 2 that started in 2017, is one of 4 in phase 3, and was the 13th registered.

Waldenstrom Macroglobulinemia

524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.

Browse Waldenstrom Macroglobulinemia studies →

Open to participants now

2 of the 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing ibrutinib in Waldenstrom Macroglobulinemia, or all of them as a file.
02

Study summary

This study evaluated the safety, efficacy and clinical benefit of BGB-3111 (zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.

Read the detailed description

This open-label, randomized study compared the efficacy and safety of the Bruton's Tyrosine Kinase (BTK) inhibitors BGB-3111 and ibrutinib in participants with Waldenström's Macroglobulinemia who require therapy. Participants had baseline bone marrow samples assayed for sequencing of the MYD88 gene. 201 participants with the MYD88 mutation were enrolled and randomized to receive 160 mg BGB-3111 orally twice per day (PO BID) (treatment Arm A) or to receive 420mg ibrutinib orally once per day (PO QD) (treatment Arm B) until disease progression or unacceptable toxicity.

03

Conditions studied

  • Waldenström's Macroglobulinemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Clinical and definitive histologic diagnosis of WM
  • , requiring treatment
  • Participants with no prior therapy for WM, must be considered inappropriate candidates for treatment with a standard chemoimmunotherapy regimen
  • Age ≥ 18 years old
  • (ECOG) performance status of 0-2
  • Adequate bone marrow function
  • Adequate renal and hepatic function
  • /multigated acquisition scan (ECHO/) demonstrating left ventricular ejection fraction (LVEF)≥ the lower limit of institutional normal
  • Participants may be enrolled who relapse after stem cell transplant if they are at least 3 months after transplant, and after allogeneic transplant if they are at least 6 months post-transplant.
  • Females of must agree to use highly effective forms of throughout the course of the study and at least up to 90 days after last dose of study drug. Males must have undergone sterilization- vasectomy, or utilize a barrier method
  • of > 4 months

Key Exclusion Criteria:

  • Prior exposure to a BTK inhibitor
  • Evidence of disease transformation at the time of study entry
  • given with antineoplastic intent within 7 days, or chemotherapy given with antineoplastic intent, targeted therapy, or radiation therapy within 3 weeks, or antibody-based therapy within 4 weeks of the start of study drug
  • Major surgery within 4 weeks of study treatment
  • Toxicity of ≥ Grade 2 from prior anticancer therapy
  • History of other active within 2 years of study entry, with exception of (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally with curative intent
  • Currently active, cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, any Class 3 or 4 cardiac disease within 6 months of screening
  • prolongation (defined as a QTcF > 480 msec)
  • Active, clinically significant Electrocardiogram (ECG) abnormalities
  • Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
  • Uncontrolled active systemic infection or recent infection requiring parenteral anti-microbial therapy
  • Known (HIV), or active or
  • Pregnant or lactating women
  • Any life-threatening illness, medical condition, organ system dysfunction, need for profound anticoagulation, or bleeding disorder, which, in the investigator's opinion, could compromise the subject's safety
  • Any medications which are strong or moderate cytochrome P450, family 3, subfamily A () inhibitors or strong CYP3A inducers

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    Arm A : Ibrutinib

    Participants with the MYD88 mutation received Ibrutinib

    Drug: Ibrutinib

  • Active comparator
    Arm B: Zanubrutinib

    Participants with the MYD88 mutation received zanubrutinib

    Drug: BGB-3111

Interventions

  • 160 mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor

    Also known as: Zanubrutinib, Brukinsa

  • 420 mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor

    Also known as: IMBRUVICA

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Either a Complete Response (CR) or Very Good Partial Response (VGPR) Using an Adaptation of the Response Criteria Updated at the Sixth International Workshop on WM as Assessed by an Independent Review Committee (IRC)

    Percentage of participants with CR, defined as normal serum immunoglobulin M (IgM) levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, or VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values.

    Time frame: Up to approximately 2 years and 7 months

Secondary outcomes

  1. Percentage of Participants Achieving Major Response Rate (MRR) as Assessed by IRC

    MRR defined as the percentage of participants achieving a best response of response of CR, defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values or partial response (PR) defined as ≥50% reduction of serum IgM from baseline.

    Time frame: Up to approximately 2 years and 7 months

  2. Duration of Response (DOR) as Assessed by IRC

    DOR defined as the time from first determination of response (CR, VGPR or PR) until first documentation of progression or death, whichever comes first. CR is defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, VGPR, is defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values or partial response (PR) is defined as ≥50% reduction of serum IgM from baseline.

    Time frame: Up to approximately 2 years and 7 months

  3. DOR as Assessed by IRC: Event -Free Rate

    Estimated percentage of participants who were event-free based on Kaplan-Meier method.

    Time frame: 12 and 18 months from the date of randomization (up to approximately 2 years and 7 months)

  4. Percentage of Participants Achieving Either CR or VGPR in as Assessed by the Investigator

    Percentage of participants with CR, defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at Baseline, or VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values.

    Time frame: Up to approximately 5 years and 5 months

  5. DOR as Assessed by the Investigator

    DOR is defined as the time from first determination of response (CR, VGPR or PR) until first documentation of progression or death, whichever comes first

    Time frame: Up to approximately 5 years and 5 months

  6. DOR as Assessed by the Investigator: Event-Free Rate

    Estimated percentage of participants who were event-free based on Kaplan-Meier method.

    Time frame: 24,36 and 48 months from the date of randomization (up to approximately 5 years and 5 months)

  7. Progression Free Survival (PFS) as Assessed by the IRC

    PFS as assessed by the IRC, defined as time from randomization to the first documentation of progression (per modified International Workshop on Waldenström macroglobulinemia \[IWWM criteria\]) or death, whichever occurs first

    Time frame: Up to approximately 2 years and 7 months

  8. PFS as Assessed by IRC: Event-Free Rate

    Estimated percentage of participants who were event-free based on Kaplan-Meier method

    Time frame: 12 and 18 months from the date of randomization (up to approximately 2 years and 7 months)

  9. PFS as Assessed by the Investigator

    PFS as assessed by the Investigator, defined as time from randomization to the first documentation of progression (per modified IWWM criteria) or death, whichever occurs first.

    Time frame: Up to approximately 5 years and 5 months

  10. PFS as Assessed by the Investigator: Event-Free Rate

    Percentage of participants who were event-free based on Kaplan-Meier method.

    Time frame: 24,36 and 48 months from the date of randomization (up to approximately 5 years and 5 months)

  11. Percentage of Participants With Resolution of All Treatment-precipitating Symptoms

    Time frame: Up to approximately 5 years and 5 months

  12. Percentage of Participants With an Anti-Lymphoma Effect

    Anti-Lymphoma Effect is defined as any reduction in bone marrow involvement by lymphoplasmacytoid lymphocytes and/or size of lymphadenopathy and/or splenomegaly by CT scan, at any time during the course of study treatment.

    Time frame: Up to approximately 5 years and 5 months

  13. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to approximately 5 years and 5 months

07

Results

Posted Jun 9, 2023

Participant flow

A total of 201 participants were randomized to Arm A and Arm B in 12 countries in Australia, Europe, United Kingdom and United States.

Participant flow — Overall Study
MilestoneArm A: IbrutinibArm B: Zanubrutinib
Started99102
Completed00
Not completed99102
Withdrew: Sponsor's decision to end the study2013
Withdrew: Death1814
Withdrew: Withdrawal by subject98
Withdrew: Lost to follow-up10
Withdrew: Enrolled in long-term extension study4866
Withdrew: Physician decision21
Withdrew: Participant randomized but died before dosing10

Outcome measures

PrimaryPercentage of Participants Achieving Either a Complete Response (CR) or Very Good Partial Response (VGPR) Using an Adaptation of the Response Criteria Updated at the Sixth International Workshop on WM as Assessed by an Independent Review Committee (IRC)

Percentage of participants with CR, defined as normal serum immunoglobulin M (IgM) levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, or VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values.

Time frame:
Up to approximately 2 years and 7 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Either a Complete Response (CR) or Very Good Partial Response (VGPR) Using an Adaptation of the Response Criteria Updated at the Sixth International Workshop on WM as Assessed by an Independent Review Committee (IRC)
Percentage of ParticipantsArm A: IbrutinibArm B: Zanubrutinib
Percentage of Participants Achieving Either a Complete Response (CR) or Very Good Partial Response (VGPR) Using an Adaptation of the Response Criteria Updated at the Sixth International Workshop on WM as Assessed by an Independent Review Committee (IRC)19.2 (12.0 to 28.3)28.4 (19.9 to 38.2)
Statistical analysis
  • Arm A: Ibrutinib vs Arm B: Zanubrutinib · Cochran-Mantel-Haenszel · p = 0.0921 · Risk difference (rd): 10.2 · 95% CI -1.5 to 22.0Based on Cochran-Mantel-Haenszel test stratified by the stratification factors per interactive response technology (IRT). p value is 2-sided
SecondaryPercentage of Participants Achieving Major Response Rate (MRR) as Assessed by IRC

MRR defined as the percentage of participants achieving a best response of response of CR, defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values or partial response (PR) defined as ≥50% reduction of serum IgM from baseline.

Time frame:
Up to approximately 2 years and 7 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Major Response Rate (MRR) as Assessed by IRC
Percentage of ParticipantsArm A: IbrutinibArm B: Zanubrutinib
Percentage of Participants Achieving Major Response Rate (MRR) as Assessed by IRC77.8 (68.3 to 85.5)77.5 (68.1 to 85.1)
SecondaryDuration of Response (DOR) as Assessed by IRC

DOR defined as the time from first determination of response (CR, VGPR or PR) until first documentation of progression or death, whichever comes first. CR is defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, VGPR, is defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values or partial response (PR) is defined as ≥50% reduction of serum IgM from baseline.

Time frame:
Up to approximately 2 years and 7 months
Reported as:
Median · Months
Duration of Response (DOR) as Assessed by IRC
MonthsArm A: IbrutinibArm B: Zanubrutinib
Duration of Response (DOR) as Assessed by IRCNA (8.0 to NA)NA (NA to NA)
SecondaryDOR as Assessed by IRC: Event -Free Rate

Estimated percentage of participants who were event-free based on Kaplan-Meier method.

Time frame:
12 and 18 months from the date of randomization (up to approximately 2 years and 7 months)
Reported as:
Number · Percentage of Participants
DOR as Assessed by IRC: Event -Free Rate
Percentage of ParticipantsArm A: IbrutinibArm B: Zanubrutinib
12 Months87.9 (77.0 to 93.8)94.4 (85.8 to 97.9)
18 Months87.9 (77.0 to 93.8)85.2 (71.7 to 92.6)
SecondaryPercentage of Participants Achieving Either CR or VGPR in as Assessed by the Investigator

Percentage of participants with CR, defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at Baseline, or VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values.

Time frame:
Up to approximately 5 years and 5 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Either CR or VGPR in as Assessed by the Investigator
Percentage of ParticipantsArm A: IbrutinibArm B: Zanubrutinib
Percentage of Participants Achieving Either CR or VGPR in as Assessed by the Investigator25.3 (17.1 to 35.0)38.2 (28.8 to 48.4)
SecondaryDOR as Assessed by the Investigator

DOR is defined as the time from first determination of response (CR, VGPR or PR) until first documentation of progression or death, whichever comes first

Time frame:
Up to approximately 5 years and 5 months
Reported as:
Median · Months
DOR as Assessed by the Investigator
MonthsArm A: IbrutinibArm B: Zanubrutinib
DOR as Assessed by the InvestigatorNA (53.5 to NA)NA (NA to NA)
SecondaryDOR as Assessed by the Investigator: Event-Free Rate

Estimated percentage of participants who were event-free based on Kaplan-Meier method.

Time frame:
24,36 and 48 months from the date of randomization (up to approximately 5 years and 5 months)
Reported as:
Number · Percentage of Participants
DOR as Assessed by the Investigator: Event-Free Rate
Percentage of ParticipantsArm A: IbrutinibArm B: Zanubrutinib
24 Months87.7 (77.8 to 93.4)89.7 (80.4 to 94.7)
36 Months77.5 (65.9 to 85.6)81.1 (70.1 to 88.4)
48 Months73.9 (61.6 to 82.8)81.1 (70.1 to 88.4)
SecondaryProgression Free Survival (PFS) as Assessed by the IRC

PFS as assessed by the IRC, defined as time from randomization to the first documentation of progression (per modified International Workshop on Waldenström macroglobulinemia \[IWWM criteria\]) or death, whichever occurs first

Time frame:
Up to approximately 2 years and 7 months
Reported as:
Median · Months
Progression Free Survival (PFS) as Assessed by the IRC
MonthsArm A: IbrutinibArm B: Zanubrutinib
Progression Free Survival (PFS) as Assessed by the IRCNA (NA to NA)NA (NA to NA)
SecondaryPFS as Assessed by IRC: Event-Free Rate

Estimated percentage of participants who were event-free based on Kaplan-Meier method

Time frame:
12 and 18 months from the date of randomization (up to approximately 2 years and 7 months)
Reported as:
Number · Percentage of Participants
PFS as Assessed by IRC: Event-Free Rate
Percentage of ParticipantsArm A: IbrutinibArm B: Zanubrutinib
12 Months87.2 (78.6 to 92.5)89.7 (81.7 to 94.3)
18 Months83.8 (74.5 to 89.9)85.0 (75.2 to 91.2)
SecondaryPFS as Assessed by the Investigator

PFS as assessed by the Investigator, defined as time from randomization to the first documentation of progression (per modified IWWM criteria) or death, whichever occurs first.

Time frame:
Up to approximately 5 years and 5 months
Reported as:
Median · Months
PFS as Assessed by the Investigator
MonthsArm A: IbrutinibArm B: Zanubrutinib
PFS as Assessed by the InvestigatorNA (54.4 to NA)NA (NA to NA)
SecondaryPFS as Assessed by the Investigator: Event-Free Rate

Percentage of participants who were event-free based on Kaplan-Meier method.

Time frame:
24,36 and 48 months from the date of randomization (up to approximately 5 years and 5 months)
Reported as:
Number · Percentage of Participants
PFS as Assessed by the Investigator: Event-Free Rate
Percentage of ParticipantsArm A: IbrutinibArm B: Zanubrutinib
24 Months80.6 (70.9 to 87.3)88.5 (80.2 to 93.5)
36 Months74.8 (64.5 to 82.5)78.3 (68.4 to 85.5)
48 Months67.3 (56.3 to 76.1)78.3 (68.4 to 85.5)
SecondaryPercentage of Participants With Resolution of All Treatment-precipitating Symptoms
Time frame:
Up to approximately 5 years and 5 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Resolution of All Treatment-precipitating Symptoms
Percentage of ParticipantsArm A: IbrutinibArm B: Zanubrutinib
Percentage of Participants With Resolution of All Treatment-precipitating Symptoms78.679.2
SecondaryPercentage of Participants With an Anti-Lymphoma Effect

Anti-Lymphoma Effect is defined as any reduction in bone marrow involvement by lymphoplasmacytoid lymphocytes and/or size of lymphadenopathy and/or splenomegaly by CT scan, at any time during the course of study treatment.

Time frame:
Up to approximately 5 years and 5 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With an Anti-Lymphoma Effect
Percentage of ParticipantsArm A: IbrutinibArm B: Zanubrutinib
Percentage of Participants With an Anti-Lymphoma Effect84.278.8
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Up to approximately 5 years and 5 months
Reported as:
Number · Number of Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Number of ParticipantsArm A: IbrutinibArm B: Zanubrutinib
Participants with At Least 1 TEAE98101
Participants with SAEs5059

Adverse events

Collected over up to approximately 5 years and 5 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Ibrutinib19/99 (19.2%)50/98 (51%)96/98 (98%)
Arm B: Zanubrutinib14/102 (13.7%)59/101 (58.4%)99/101 (98%)
Most frequent serious events
Showing 10 of 141
Most frequent serious events
EventArm A: IbrutinibArm B: Zanubrutinib
PneumoniaInfections and infestations14/982/101
Atrial fibrillationCardiac disorders5/982/101
SepsisInfections and infestations4/983/101
PyrexiaGeneral disorders3/984/101
Acute myocardial infarctionCardiac disorders3/982/101
PericarditisCardiac disorders3/980/101
Bladder transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/980/101
SyncopeNervous system disorders3/983/101
Febrile neutropeniaBlood and lymphatic system disorders0/983/101
NeutropeniaBlood and lymphatic system disorders0/983/101
Most frequent other events
Showing 10 of 159
Most frequent other events
EventArm A: IbrutinibArm B: Zanubrutinib
DiarrhoeaGastrointestinal disorders36/9823/101
Upper respiratory tract infectionInfections and infestations31/9833/101
NeutropeniaBlood and lymphatic system disorders16/9829/101
Muscle spasmsMusculoskeletal and connective tissue disorders28/9812/101
ContusionInjury, poisoning and procedural complications27/9819/101
FatigueGeneral disorders19/9826/101
ArthralgiaMusculoskeletal and connective tissue disorders24/9824/101
HypertensionVascular disorders24/9816/101
AnaemiaBlood and lymphatic system disorders22/9818/101
Oedema peripheralGeneral disorders22/9819/101

Baseline characteristics

Intent to Treat (ITT) Analysis Set: Includes all randomized participants assigned to an arm.

Age, Continuous
Age, Continuous(years)Arm A: IbrutinibArm B: ZanubrutinibTotal
Mean69.9 ± 8.5869.2 ± 10.2669.5 ± 9.46
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: IbrutinibArm B: ZanubrutinibTotal
Female343367
Male6569134
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: IbrutinibArm B: ZanubrutinibTotal
Hispanic or Latino448
Not Hispanic or Latino9182173
Unknown or Not Reported41620
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: IbrutinibArm B: ZanubrutinibTotal
American Indian or Alaska Native000
Asian044
Native Hawaiian or Other Pacific Islander000
Black or African American000
White9488182
More than one race000
Unknown or Not Reported51015
08

Study locations

58 sites
  • Mayo Clinic Phoenix
    Phoenix, Arizona 85254, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Paratus Clinical Research Woden
    Canberra, Australian Capital Territory 2606, Australia
  • St George Hospital
    Kogarah, New South Wales 2217, Australia
  • Royal North Shore Hospital
    St Leonards, New South Wales 2065, Australia
  • Princess Alexandra Hospital
    Brisbane, Queensland 4102, Australia
  • Flinders Medical Centre
    Bedford PK, South Australia 5042, Australia
  • Monash Health
    Clayton, Victoria 3168, Australia
  • St Vincents Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
  • Peninsula Health Frankston
    Frankston, Victoria 3199, Australia
  • Barwon Health the Geelong Hospital
    Geelong, Victoria 3220, Australia
  • Peter Maccallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • Fakultni Nemocnice Hradec Kralove
    Hradec Kralove, 50005, Czechia
  • Fakultni Nemocnice Ostrava
    Ostrava, 708 00, Czechia
  • Vseobecna Fakultni Nemocnice V Praze
    Praha, 10000, Czechia
  • Centre Leon Berard
    Lyon Cedex, 69373, France
  • Srh Kliniken Landkreis Sigmaringen
    Sigmaringen, 72488, Germany
  • Universitaetsklinikum Ulm, Innere Medizin Iii
    Ulm, 89081, Germany
  • General Hospital of Athens Alexandra
    Athens, 11528, Greece
  • Policlinico Sorsola Malpighi, Aou Di Bologna
    Bologna, 40138, Italy
  • Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
    Brescia, 25123, Italy
  • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst
    Meldola, 47014, Italy
  • Niguarda Cancer Center Division of Hematology
    Milano, 20162, Italy
  • Aou Maggiore Della Carita
    Novara, 28100, Italy
  • Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi
    Pavia, 27100, Italy
  • Unita Di Ematologia, Dipartimento Di Ematologia Ed Oncologia
    Ravenna, 48121, Italy
  • Fondazione Policlinico A Gemelli
    Roma, 168, Italy
  • Ao Citta Della Salute E Della Scienza Di Torino Presidio O
    Torino, 10126, Italy
  • Aou Santa Maria Della Misericordia Di Udine
    Udine, 33100, Italy
  • Amsterdam Umc Amc
    Amsterdam, 1105 AZ, Netherlands
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584 CX, Netherlands
  • Uniwersytecki Szpital Kliniczny W Bialymstoku
    Bialystok, 15-276, Poland
  • Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
    Brzozow, 36-200, Poland
  • Szpital Uniwersytecki Nr Im Dr Jana Biziela
    Bydgoszcz, 85-168, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich
    Chorzow, 41-500, Poland
  • Malopolskie Centrum Medyczne Sc
    Krakow, 30-510, Poland
  • Hospital Universitari Germans Trias I Pujol
    Badalona, 08916, Spain
  • Hospital de La Santa Creu I Sant Pau
    Barcelona, 08025, Spain
  • Hospital Universitario Vall Dhebron
    Barcelona, 08035, Spain
  • Ico H Duran I Reynals
    Barcelona, 08907, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 8036, Spain
  • Start Madrid Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitari I Politecnic La Fe
    Valencia, 46026, Spain
  • Karolinska Universitetssjukhuset Solna
    Stockholm, 171 76, Sweden
  • The Royal Bournemouth and Christchurch Hospitals Nhs Foundation
    Bournemouth, BH7 7DW, United Kingdom
  • Churchill Hospital Oxford University Hospital Nhs Trust
    Headington, OX3 7LE, United Kingdom
  • St Jamess Institute of Oncology
    Leeds, LS9 7LP, United Kingdom
  • Barts Health Nhs Trust
    London, EC1A 7BE, United Kingdom
  • University College Hospital
    London, NW1 2PG, United Kingdom
  • Nottingham University Hospitals Nhs Trust
    Nottingham, NG51PB, United Kingdom
  • Plymouth Hospitals Nhs Trust
    Plymouth, PL6 8DH, United Kingdom
09

References and documents

Publications

  • Tam CS, LeBlond V, Novotny W, Owen RG, Tedeschi A, Atwal S, Cohen A, Huang J, Buske C. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenstrom macroglobulinemia. Future Oncol. 2018 Sep;14(22):2229-2237. doi: 10.2217/fon-2018-0163. Epub 2018 Jun 5. PubMed 29869556 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Jun 2022, 64 months.

Results were first posted in Jun 2023, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2017
First posted
Feb 15, 2017
StartActual
Jan 25, 2017
Primary completionActual
Jun 21, 2022
CompletionActual
Jun 21, 2022
Results first posted
Jun 9, 2023
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03053440
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Feb 15, 2017
Start date
Jan 25, 2017
Primary completion
Jun 21, 2022
Completion
Jun 21, 2022
Results posted
Jun 9, 2023
Last update
Oct 26, 2024

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion